/
/
An Update on Primary Plasma Cell Leukemia Treatment Options
An Update on Primary Plasma Cell Leukemia Treatment Options image
An Update on Primary Plasma Cell Leukemia Treatment Options
Posted Sep 19, 2017

BY PAUL KLEUTGHEN For the 150, or so, with primary Plasma Cell Leukemia... An interesting article was recently published in the American Journal of Hematology/Oncology for the few of us walking around with primary plasma cell leukemia (pPCL). The article is easy to read and understand and provides insight into current treatment options and what we can expect as future potential treatment options. The author, who is with is with the Divisions of Hematology and Blood and Marrow Transplantation, Mayo Clinic, Rochester, Minnesota makes some key observations :

‘The correct and timely diagnosis of pPCL is highly dependent upon the ability of the hematologist or pathologist to identify circulating plasma cells on a peripheral blood smear. This expertise varies among individuals and institutions, making the likelihood of diagnosis not uniform. In the future, routine quantification of circulating clonal plasma cells by flow cytometry could identify a new cutoff to define PCL that would be more amenable to identification. Finally, given that patients with pPCL do not benefit as much from the currently available treatment strategies compared with other patients with MM, these patients should be considered for enrollment in therapeutic clinical trials. It remains unknown as to where the incorporation of novel antibodies, such as elotuzumab and daratumumab, will fit in the treatment schema of patients with pPCL. Similarly, the emergence of adoptive immunotherapy modalities, such as chimeric antigen receptor T-cell therapy targeting either B-cell maturation antigen or CD19 plasma cell antigens, appears to hold promise as therapies for pPCL in the future. One particular agent of considerable interest will be venetoclax, a selective BCL-2 inhibitor, which has shown encouraging efficacy in MM, especially in clonal plasma cells harboring a t(11,14) cytogenetic abnormality that coincidentally is the most common abnormality in pPCL.’ [emphasis added]

The full article can be accessed HERE.

The author Paul Kleutghen

about the author
Paul Kleutghen

I am a patient diagnosed in 2014 with primary plasma cell leukemia (pPCL), a rare and aggressive variant of multiple myeloma and have been very fortunate to find successful treatment at the division of Cellular Therapy at the Duke University Cancer Institute. My wife, Vicki, and I have two adult children and two grandsons who are the ‘lights of our lives’. Successful treatment has allowed Vicki and I to do what we love best : traveling the world, albeit it with some extra precautions to keep infections away. My career in the pharmaceutical industry has given me insights that I am currently putting to use as an advocate to lower drug pricing, especially prices for anti-cancer drugs. I am a firm believer that staying mentally active, physically fit, compliant to our treatment regimen and taking an active interest in our disease are keys to successful treatment outcomes.

More Life with Myeloma Articles

Get the latest thought leadership on Myeloma delivered straight to your inbox.

Subscribe to the weekly "HealthTree Community for Myeloma Newsletter" for Myeloma news, life with Myeloma stories, Myeloma clinical trials, Myeloma 101 articles and events with Myeloma experts.

Thanks to our HealthTree Community for Myeloma Sponsors:

Genentech
Abbvie
Bristol Myers Squibb
Janssen Oncology
GSK

Follow Us

facebook instagram twitter youtube

Copyright © 2022 HealthTree Foundation. All Rights Reserved.

The HealthTree Foundation / Myeloma Crowd is a qualified 501(c)(3) tax-exempt organization. Tax ID 45-5354811

 https://www.guidestar.org/profile/45-5354811